Skip to main content
Top
Published in: Respiratory Research 1/2011

Open Access 01-12-2011 | Research

Prevention of bronchial hyperreactivity in a rat model of precapillary pulmonary hypertension

Authors: Walid Habre, Gergely Albu, Tibor Z Janosi, Fabienne Fontao, Britta S von Ungern-Sternberg, Maurice Beghetti, Ferenc Petak

Published in: Respiratory Research | Issue 1/2011

Login to get access

Abstract

Background

The development of bronchial hyperreactivity (BHR) subsequent to precapillary pulmonary hypertension (PHT) was prevented by acting on the major signalling pathways (endothelin, nitric oxide, vasoactive intestine peptide (VIP) and prostacyclin) involved in the control of the pulmonary vascular and bronchial tones.

Methods

Five groups of rats underwent surgery to prepare an aorta-caval shunt (ACS) to induce sustained precapillary PHT for 4 weeks. During this period, no treatment was applied in one group (ACS controls), while the other groups were pretreated with VIP, iloprost, tezosentan via an intraperitoneally implemented osmotic pump, or by orally administered sildenafil. An additional group underwent sham surgery. Four weeks later, the lung responsiveness to increasing doses of an intravenous infusion of methacholine (2, 4, 8 12 and 24 μg/kg/min) was determined by using the forced oscillation technique to assess the airway resistance (Raw).

Results

BHR developed in the untreated rats, as reflected by a significant decrease in ED50, the equivalent dose of methacholine required to cause a 50% increase in Raw. All drugs tested prevented the development of BHR, iloprost being the most effective in reducing both the systolic pulmonary arterial pressure (Ppa; 28%, p = 0.035) and BHR (ED50 = 9.9 ± 1.7 vs. 43 ± 11 μg/kg in ACS control and iloprost-treated rats, respectively, p = 0.008). Significant correlations were found between the levels of Ppa and ED50 (R = -0.59, p = 0.016), indicating that mechanical interdependence is primarily responsible for the development of BHR.

Conclusions

The efficiency of such treatment demonstrates that re-establishment of the balance of constrictor/dilator mediators via various signalling pathways involved in PHT is of potential benefit for the avoidance of the development of BHR.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hoeper MM, Rubin LJ: Update in pulmonary hypertension 2005. Am J Respir Crit Care Med. 2006, 173: 499-505. 10.1164/rccm.2512003.CrossRefPubMed Hoeper MM, Rubin LJ: Update in pulmonary hypertension 2005. Am J Respir Crit Care Med. 2006, 173: 499-505. 10.1164/rccm.2512003.CrossRefPubMed
2.
go back to reference McLaughlin VV, Genthner DE, Panella MM, Rich S: Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 1998, 338: 273-277. 10.1056/NEJM199801293380501.CrossRefPubMed McLaughlin VV, Genthner DE, Panella MM, Rich S: Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med. 1998, 338: 273-277. 10.1056/NEJM199801293380501.CrossRefPubMed
3.
go back to reference Murali S: Pulmonary arterial hypertension. Curr Opin Crit Care. 2006, 12: 228-234. 10.1097/01.ccx.0000224867.78581.0c.CrossRefPubMed Murali S: Pulmonary arterial hypertension. Curr Opin Crit Care. 2006, 12: 228-234. 10.1097/01.ccx.0000224867.78581.0c.CrossRefPubMed
4.
go back to reference Rich S: The current treatment of pulmonary arterial hypertension: time to redefine success. Chest. 2006, 130: 1198-1202. 10.1378/chest.130.4.1198.CrossRefPubMed Rich S: The current treatment of pulmonary arterial hypertension: time to redefine success. Chest. 2006, 130: 1198-1202. 10.1378/chest.130.4.1198.CrossRefPubMed
5.
go back to reference Humbert M, Sitbon O, Simonneau G: Treatment of pulmonary arterial hypertension. N Engl J Med. 2004, 351: 1425-1436. 10.1056/NEJMra040291.CrossRefPubMed Humbert M, Sitbon O, Simonneau G: Treatment of pulmonary arterial hypertension. N Engl J Med. 2004, 351: 1425-1436. 10.1056/NEJMra040291.CrossRefPubMed
6.
go back to reference Howard LS, Morrell NW: New therapeutic agents for pulmonary vascular disease. Paediatr Respir Rev. 2005, 6: 285-291. 10.1016/j.prrv.2005.09.006.CrossRefPubMed Howard LS, Morrell NW: New therapeutic agents for pulmonary vascular disease. Paediatr Respir Rev. 2005, 6: 285-291. 10.1016/j.prrv.2005.09.006.CrossRefPubMed
7.
go back to reference Keith IM: The role of endogenous lung neuropeptides in regulation of the pulmonary circulation. Physiol Res. 2000, 49: 519-537.PubMed Keith IM: The role of endogenous lung neuropeptides in regulation of the pulmonary circulation. Physiol Res. 2000, 49: 519-537.PubMed
8.
go back to reference Habre W, Petak F, Ruchonnet-Metrailler I, Donati Y, Tolsa JF, Lele E, Albu G, Beghetti M, Barazzone-Argiroffo C: The role of endothelin-1 in hyperoxia-induced lung injury in mice. Respir Res. 2006, 7: 45-10.1186/1465-9921-7-45.CrossRefPubMedPubMedCentral Habre W, Petak F, Ruchonnet-Metrailler I, Donati Y, Tolsa JF, Lele E, Albu G, Beghetti M, Barazzone-Argiroffo C: The role of endothelin-1 in hyperoxia-induced lung injury in mice. Respir Res. 2006, 7: 45-10.1186/1465-9921-7-45.CrossRefPubMedPubMedCentral
9.
go back to reference Ghofrani HA, Osterloh IH, Grimminger F: Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov. 2006, 5: 689-702. 10.1038/nrd2030.CrossRefPubMed Ghofrani HA, Osterloh IH, Grimminger F: Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov. 2006, 5: 689-702. 10.1038/nrd2030.CrossRefPubMed
10.
go back to reference Janosi T, Petak F, Fontao F, Morel DR, Beghetti M, Habre W: Differential roles of endothelin-1 ETA and ETB receptors and vasoactive intestinal polypeptide in regulation of the airways and the pulmonary vasculature in isolated rat lung. Exp Physiol. 2008, 93: 1210-1219. 10.1113/expphysiol.2008.042481.CrossRefPubMed Janosi T, Petak F, Fontao F, Morel DR, Beghetti M, Habre W: Differential roles of endothelin-1 ETA and ETB receptors and vasoactive intestinal polypeptide in regulation of the airways and the pulmonary vasculature in isolated rat lung. Exp Physiol. 2008, 93: 1210-1219. 10.1113/expphysiol.2008.042481.CrossRefPubMed
11.
go back to reference von Ungern-Sternberg BS, Habre W, Regli A, Pache JC, Fontao F, Janosi TZ, Beghetti M, Petak F: Precapillary pulmonary hypertension leads to reversible bronchial hyperreactivity in rats. Exp Lung Res. 2010, 36: 129-139. 10.3109/01902140903214667.CrossRefPubMed von Ungern-Sternberg BS, Habre W, Regli A, Pache JC, Fontao F, Janosi TZ, Beghetti M, Petak F: Precapillary pulmonary hypertension leads to reversible bronchial hyperreactivity in rats. Exp Lung Res. 2010, 36: 129-139. 10.3109/01902140903214667.CrossRefPubMed
12.
go back to reference Garcia R, Diebold S: Simple, rapid, and effective method of producing aortocaval shunts in the rat. Cardiovasc Res. 1990, 24: 430-432. 10.1093/cvr/24.5.430.CrossRefPubMed Garcia R, Diebold S: Simple, rapid, and effective method of producing aortocaval shunts in the rat. Cardiovasc Res. 1990, 24: 430-432. 10.1093/cvr/24.5.430.CrossRefPubMed
13.
go back to reference Ocampo C, Ingram P, Ilbawi M, Arcilla R, Gupta M: Revisiting the surgical creation of volume load by aorto-caval shunt in rats. Mol Cell Biochem. 2003, 251: 139-143. 10.1023/A:1025450403668.CrossRefPubMed Ocampo C, Ingram P, Ilbawi M, Arcilla R, Gupta M: Revisiting the surgical creation of volume load by aorto-caval shunt in rats. Mol Cell Biochem. 2003, 251: 139-143. 10.1023/A:1025450403668.CrossRefPubMed
14.
go back to reference Habre W, Janosi TZ, Fontao F, Meyers C, Albu G, Pache JC, Petak F: Mechanisms for lung function impairment and airway hyperresponsiveness following chronic hypoxia in rats. Am J Physiol Lung Cell Mol Physiol. 2010, 298: L607-614. 10.1152/ajplung.00222.2009.CrossRefPubMed Habre W, Janosi TZ, Fontao F, Meyers C, Albu G, Pache JC, Petak F: Mechanisms for lung function impairment and airway hyperresponsiveness following chronic hypoxia in rats. Am J Physiol Lung Cell Mol Physiol. 2010, 298: L607-614. 10.1152/ajplung.00222.2009.CrossRefPubMed
15.
go back to reference Janosi TZ, Adamicza A, Zosky GR, Asztalos T, Sly PD, Hantos Z: Plethysmographic estimation of thoracic gas volume in apneic mice. J Appl Physiol. 2006, 101: 454-459. 10.1152/japplphysiol.00011.2006.CrossRefPubMed Janosi TZ, Adamicza A, Zosky GR, Asztalos T, Sly PD, Hantos Z: Plethysmographic estimation of thoracic gas volume in apneic mice. J Appl Physiol. 2006, 101: 454-459. 10.1152/japplphysiol.00011.2006.CrossRefPubMed
16.
go back to reference Petak F, Hantos Z, Adamicza A, Asztalos T, Sly PD: Methacholine-induced bronchoconstriction in rats: effects of intravenous vs. aerosol delivery. J Appl Physiol. 1997, 82: 1479-1487. 10.1063/1.365927.CrossRefPubMed Petak F, Hantos Z, Adamicza A, Asztalos T, Sly PD: Methacholine-induced bronchoconstriction in rats: effects of intravenous vs. aerosol delivery. J Appl Physiol. 1997, 82: 1479-1487. 10.1063/1.365927.CrossRefPubMed
17.
go back to reference Petak F, Habre W, Hantos Z, Sly PD, Morel DR: Effects of pulmonary vascular pressures and flow on airway and parenchymal mechanics in isolated rat lungs. J Appl Physiol. 2002, 92: 169-178.PubMed Petak F, Habre W, Hantos Z, Sly PD, Morel DR: Effects of pulmonary vascular pressures and flow on airway and parenchymal mechanics in isolated rat lungs. J Appl Physiol. 2002, 92: 169-178.PubMed
18.
go back to reference Hantos Z, Daroczy B, Suki B, Nagy S, Fredberg JJ: Input impedance and peripheral inhomogeneity of dog lungs. J Appl Physiol. 1992, 72: 168-178. 10.1063/1.352153.CrossRefPubMed Hantos Z, Daroczy B, Suki B, Nagy S, Fredberg JJ: Input impedance and peripheral inhomogeneity of dog lungs. J Appl Physiol. 1992, 72: 168-178. 10.1063/1.352153.CrossRefPubMed
19.
go back to reference Petak F, Hall GL, Sly PD: Repeated measurements of airway and parenchymal mechanics in rats by using low-frequency oscillations. J Appl Physiol. 1998, 84: 1680-1686. 10.1063/1.368257.CrossRefPubMed Petak F, Hall GL, Sly PD: Repeated measurements of airway and parenchymal mechanics in rats by using low-frequency oscillations. J Appl Physiol. 1998, 84: 1680-1686. 10.1063/1.368257.CrossRefPubMed
20.
go back to reference Lam CF, Peterson TE, Croatt AJ, Nath KA, Katusic ZS: Functional adaptation and remodeling of pulmonary artery in flow-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2005, 289: H2334-2341. 10.1152/ajpheart.00375.2005.CrossRefPubMed Lam CF, Peterson TE, Croatt AJ, Nath KA, Katusic ZS: Functional adaptation and remodeling of pulmonary artery in flow-induced pulmonary hypertension. Am J Physiol Heart Circ Physiol. 2005, 289: H2334-2341. 10.1152/ajpheart.00375.2005.CrossRefPubMed
21.
go back to reference Larsen GL, Loader J, Fratelli C, Kang JK, Dakhama A, Colasurdo GN: Modulation of airway responses by prostaglandins in young and fully grown rabbits. Am J Physiol Lung Cell Mol Physiol. 2007, 293: L239-244. 10.1152/ajplung.00413.2006.CrossRefPubMed Larsen GL, Loader J, Fratelli C, Kang JK, Dakhama A, Colasurdo GN: Modulation of airway responses by prostaglandins in young and fully grown rabbits. Am J Physiol Lung Cell Mol Physiol. 2007, 293: L239-244. 10.1152/ajplung.00413.2006.CrossRefPubMed
22.
go back to reference Ricciardolo FL, Sterk PJ, Gaston B, Folkerts G: Nitric oxide in health and disease of the respiratory system. Physiol Rev. 2004, 84: 731-765. 10.1152/physrev.00034.2003.CrossRefPubMed Ricciardolo FL, Sterk PJ, Gaston B, Folkerts G: Nitric oxide in health and disease of the respiratory system. Physiol Rev. 2004, 84: 731-765. 10.1152/physrev.00034.2003.CrossRefPubMed
23.
go back to reference Higenbottam TW, Butt AY, Dinh-Xaun AT, Takao M, Cremona G, Akamine S: Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart. 1998, 79: 175-179.CrossRefPubMedPubMedCentral Higenbottam TW, Butt AY, Dinh-Xaun AT, Takao M, Cremona G, Akamine S: Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost. Heart. 1998, 79: 175-179.CrossRefPubMedPubMedCentral
24.
go back to reference Gomberg-Maitland M, Olschewski H: Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J. 2008, 31: 891-901. 10.1183/09031936.00097107.CrossRefPubMed Gomberg-Maitland M, Olschewski H: Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J. 2008, 31: 891-901. 10.1183/09031936.00097107.CrossRefPubMed
25.
go back to reference Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993, 328: 1732-1739. 10.1056/NEJM199306173282402.CrossRefPubMed Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993, 328: 1732-1739. 10.1056/NEJM199306173282402.CrossRefPubMed
26.
go back to reference Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, et al: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005, 353: 2148-2157. 10.1056/NEJMoa050010.CrossRefPubMed Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, et al: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005, 353: 2148-2157. 10.1056/NEJMoa050010.CrossRefPubMed
27.
go back to reference Brown RH, Zerhouni EA, Hirshman CA: Reversal of bronchoconstriction by inhaled nitric oxide. Histamine versus methacholine. Am J Respir Crit Care Med. 1994, 150: 233-237.CrossRefPubMed Brown RH, Zerhouni EA, Hirshman CA: Reversal of bronchoconstriction by inhaled nitric oxide. Histamine versus methacholine. Am J Respir Crit Care Med. 1994, 150: 233-237.CrossRefPubMed
28.
go back to reference Hogman M, Frostell C, Arnberg H, Hedenstierna G: Inhalation of nitric oxide modulates methacholine-induced bronchoconstriction in the rabbit. Eur Respir J. 1993, 6: 177-180.PubMed Hogman M, Frostell C, Arnberg H, Hedenstierna G: Inhalation of nitric oxide modulates methacholine-induced bronchoconstriction in the rabbit. Eur Respir J. 1993, 6: 177-180.PubMed
29.
go back to reference MacLean MR, McCulloch KM, Baird M: Endothelin ETA- and ETB-receptor-mediated vasoconstriction in rat pulmonary arteries and arterioles. J Cardiovasc Pharmacol. 1994, 23: 838-845. 10.1097/00005344-199405000-00022.CrossRefPubMed MacLean MR, McCulloch KM, Baird M: Endothelin ETA- and ETB-receptor-mediated vasoconstriction in rat pulmonary arteries and arterioles. J Cardiovasc Pharmacol. 1994, 23: 838-845. 10.1097/00005344-199405000-00022.CrossRefPubMed
30.
go back to reference Leuchte HH, Meis T, El-Nounou M, Michalek J, Behr J: Inhalation of endothelin receptor blockers in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2008, 294: L772-777. 10.1152/ajplung.00405.2007.CrossRefPubMed Leuchte HH, Meis T, El-Nounou M, Michalek J, Behr J: Inhalation of endothelin receptor blockers in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2008, 294: L772-777. 10.1152/ajplung.00405.2007.CrossRefPubMed
31.
go back to reference Opitz CF, Ewert R, Kirch W, Pittrow D: Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?. Eur Heart J. 2008, 29: 1936-1948. 10.1093/eurheartj/ehn234.CrossRefPubMedPubMedCentral Opitz CF, Ewert R, Kirch W, Pittrow D: Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?. Eur Heart J. 2008, 29: 1936-1948. 10.1093/eurheartj/ehn234.CrossRefPubMedPubMedCentral
32.
go back to reference Anaid S, Petkov V, Baykuscheva-Gentscheva T, Hoeger H, Painsipp E, Holzer P, Mosgoeller W: Involvement of endothelial NO in the dilator effect of VIP on rat isolated pulmonary artery. Regul Pept. 2007, 139: 102-108. 10.1016/j.regpep.2006.10.012.CrossRef Anaid S, Petkov V, Baykuscheva-Gentscheva T, Hoeger H, Painsipp E, Holzer P, Mosgoeller W: Involvement of endothelial NO in the dilator effect of VIP on rat isolated pulmonary artery. Regul Pept. 2007, 139: 102-108. 10.1016/j.regpep.2006.10.012.CrossRef
33.
go back to reference Iwabuchi S, Ono S, Tanita T, Koike K, Fujimura S: Vasoactive intestinal peptide causes nitric oxide-dependent pulmonary vasodilation in isolated rat lung. Respiration. 1997, 64: 54-58. 10.1159/000196643.CrossRefPubMed Iwabuchi S, Ono S, Tanita T, Koike K, Fujimura S: Vasoactive intestinal peptide causes nitric oxide-dependent pulmonary vasodilation in isolated rat lung. Respiration. 1997, 64: 54-58. 10.1159/000196643.CrossRefPubMed
34.
go back to reference Crimi N, Palermo F, Oliveri R, Palermo B, Vancheri C, Polosa R, Mistretta A: Effect of vasoactive intestinal peptide (VIP) on propranolol-induced bronchoconstriction. J Allergy Clin Immunol. 1988, 82: 617-621. 10.1016/0091-6749(88)90973-6.CrossRefPubMed Crimi N, Palermo F, Oliveri R, Palermo B, Vancheri C, Polosa R, Mistretta A: Effect of vasoactive intestinal peptide (VIP) on propranolol-induced bronchoconstriction. J Allergy Clin Immunol. 1988, 82: 617-621. 10.1016/0091-6749(88)90973-6.CrossRefPubMed
35.
go back to reference Hagen BM, Bayguinov O, Sanders KM: VIP and PACAP regulate localized Ca2+ transients via cAMP-dependent mechanism. Am J Physiol Cell Physiol. 2006, 291: C375-385. 10.1152/ajpcell.00495.2005.CrossRefPubMed Hagen BM, Bayguinov O, Sanders KM: VIP and PACAP regulate localized Ca2+ transients via cAMP-dependent mechanism. Am J Physiol Cell Physiol. 2006, 291: C375-385. 10.1152/ajpcell.00495.2005.CrossRefPubMed
36.
go back to reference Kishi M, Takeuchi T, Suthamnatpong N, Ishii T, Nishio H, Hata F, Takewaki T: VIP- and PACAP-mediated nonadrenergic, noncholinergic inhibition in longitudinal muscle of rat distal colon: involvement of activation of charybdotoxin- and apamin-sensitive K+ channels. Br J Pharmacol. 1996, 119: 623-630.CrossRefPubMedPubMedCentral Kishi M, Takeuchi T, Suthamnatpong N, Ishii T, Nishio H, Hata F, Takewaki T: VIP- and PACAP-mediated nonadrenergic, noncholinergic inhibition in longitudinal muscle of rat distal colon: involvement of activation of charybdotoxin- and apamin-sensitive K+ channels. Br J Pharmacol. 1996, 119: 623-630.CrossRefPubMedPubMedCentral
37.
go back to reference Lee TJ: Nitric oxide and the cerebral vascular function. J Biomed Sci. 2000, 7: 16-26. 10.1007/BF02255914.CrossRefPubMed Lee TJ: Nitric oxide and the cerebral vascular function. J Biomed Sci. 2000, 7: 16-26. 10.1007/BF02255914.CrossRefPubMed
38.
go back to reference Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, Funk GC, Hamilton G, Novotny C, Burian B, Block LH: Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest. 2003, 111: 1339-1346.CrossRefPubMedPubMedCentral Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, Funk GC, Hamilton G, Novotny C, Burian B, Block LH: Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest. 2003, 111: 1339-1346.CrossRefPubMedPubMedCentral
39.
go back to reference Leuchte HH, Baezner C, Baumgartner RA, Bevec D, Bacher G, Neurohr C, Behr J: Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J. 2008, 32: 1289-1294. 10.1183/09031936.00050008.CrossRefPubMed Leuchte HH, Baezner C, Baumgartner RA, Bevec D, Bacher G, Neurohr C, Behr J: Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J. 2008, 32: 1289-1294. 10.1183/09031936.00050008.CrossRefPubMed
40.
go back to reference Barnes PJ, Dixon CM: The effect of inhaled vasoactive intestinal peptide on bronchial reactivity to histamine in humans. Am Rev Respir Dis. 1984, 130: 162-166.PubMed Barnes PJ, Dixon CM: The effect of inhaled vasoactive intestinal peptide on bronchial reactivity to histamine in humans. Am Rev Respir Dis. 1984, 130: 162-166.PubMed
Metadata
Title
Prevention of bronchial hyperreactivity in a rat model of precapillary pulmonary hypertension
Authors
Walid Habre
Gergely Albu
Tibor Z Janosi
Fabienne Fontao
Britta S von Ungern-Sternberg
Maurice Beghetti
Ferenc Petak
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2011
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-12-58

Other articles of this Issue 1/2011

Respiratory Research 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine